Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer

M. P. Myklebust; Z. Li; T. H. Tran; H. Rui; E. S. Knudsen; H. Elsaleh; [No Value] Fluge; B. Vonen; H. E. Myrvold; S. Leh; K. M. Tveit; R. G. Pestell; O. Dahl

doi:10.1038/bjc.2012.463

Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer

M. P. Myklebust, Z. Li, T. H. Tran, H. Rui, E. S. Knudsen, H. Elsaleh, [No Value] Fluge, B. Vonen, H. E. Myrvold, S. Leh, K. M. Tveit, R. G. Pestell, O. Dahl

Pathology

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Abstract

Background:The aim of this study was to investigate the value of the cyclin D1 isoforms D1a and D1b as prognostic factors and their relevance as predictors of response to adjuvant chemotherapy with 5-fluorouracil and levamisole (5-FU/LEV) in colorectal cancer (CRC).Methods:Protein expression of nuclear cyclin D1a and D1b was assessed by immunohistochemistry in 335 CRC patients treated with surgery alone or with adjuvant therapy using 5-FU/LEV. The prognostic and predictive value of these two molecular markers and clinicopathological factors were evaluated statistically in univariate and multivariate survival analyses.Results:Neither cyclin D1a nor D1b showed any prognostic value in CRC or colon cancer patients. However, high cyclin D1a predicted benefit from adjuvant therapy measured in 5-year relapse-free survival (RFS) and CRC-specific survival (CSS) compared to surgery alone in colon cancer (P0.012 and P0.038, respectively) and especially in colon cancer stage III patients (P0.005 and P0.019, respectively) in univariate analyses. An interaction between treatment group and cyclin D1a could be shown for RFS (P0.004) and CSS (P0.025) in multivariate analysis.Conclusion:Our study identifies high cyclin D1a protein expression as a positive predictive factor for the benefit of adjuvant 5-FU/LEV treatment in colon cancer, particularly in stage III colon cancer.

Original language	English (US)
Pages (from-to)	1684-1691
Number of pages	8
Journal	British journal of cancer
Volume	107
Issue number	10
DOIs	https://doi.org/10.1038/bjc.2012.463
State	Published - Nov 6 2012

Keywords

Colorectal cancer
Cyclin D1a
Cyclin D1b
IHC
Treatment response

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1038/bjc.2012.463

Cite this

@article{1dc4a3ebe724450d90611c5bdd1f1572,

title = "Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer",

abstract = "Background:The aim of this study was to investigate the value of the cyclin D1 isoforms D1a and D1b as prognostic factors and their relevance as predictors of response to adjuvant chemotherapy with 5-fluorouracil and levamisole (5-FU/LEV) in colorectal cancer (CRC).Methods:Protein expression of nuclear cyclin D1a and D1b was assessed by immunohistochemistry in 335 CRC patients treated with surgery alone or with adjuvant therapy using 5-FU/LEV. The prognostic and predictive value of these two molecular markers and clinicopathological factors were evaluated statistically in univariate and multivariate survival analyses.Results:Neither cyclin D1a nor D1b showed any prognostic value in CRC or colon cancer patients. However, high cyclin D1a predicted benefit from adjuvant therapy measured in 5-year relapse-free survival (RFS) and CRC-specific survival (CSS) compared to surgery alone in colon cancer (P0.012 and P0.038, respectively) and especially in colon cancer stage III patients (P0.005 and P0.019, respectively) in univariate analyses. An interaction between treatment group and cyclin D1a could be shown for RFS (P0.004) and CSS (P0.025) in multivariate analysis.Conclusion:Our study identifies high cyclin D1a protein expression as a positive predictive factor for the benefit of adjuvant 5-FU/LEV treatment in colon cancer, particularly in stage III colon cancer.",

keywords = "Colorectal cancer, Cyclin D1a, Cyclin D1b, IHC, Treatment response",

author = "Myklebust, {M. P.} and Z. Li and Tran, {T. H.} and H. Rui and Knudsen, {E. S.} and H. Elsaleh and Fluge, {[No Value]} and B. Vonen and Myrvold, {H. E.} and S. Leh and Tveit, {K. M.} and Pestell, {R. G.} and O. Dahl",

note = "Funding Information: This project was funded by the Norwegian Cancer Society.",

year = "2012",

month = nov,

day = "6",

doi = "10.1038/bjc.2012.463",

language = "English (US)",

volume = "107",

pages = "1684--1691",

journal = "British journal of cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "10",

}

TY - JOUR

T1 - Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer

AU - Myklebust, M. P.

AU - Li, Z.

AU - Tran, T. H.

AU - Rui, H.

AU - Knudsen, E. S.

AU - Elsaleh, H.

AU - Fluge, [No Value]

AU - Vonen, B.

AU - Myrvold, H. E.

AU - Leh, S.

AU - Tveit, K. M.

AU - Pestell, R. G.

AU - Dahl, O.

N1 - Funding Information: This project was funded by the Norwegian Cancer Society.

PY - 2012/11/6

Y1 - 2012/11/6

N2 - Background:The aim of this study was to investigate the value of the cyclin D1 isoforms D1a and D1b as prognostic factors and their relevance as predictors of response to adjuvant chemotherapy with 5-fluorouracil and levamisole (5-FU/LEV) in colorectal cancer (CRC).Methods:Protein expression of nuclear cyclin D1a and D1b was assessed by immunohistochemistry in 335 CRC patients treated with surgery alone or with adjuvant therapy using 5-FU/LEV. The prognostic and predictive value of these two molecular markers and clinicopathological factors were evaluated statistically in univariate and multivariate survival analyses.Results:Neither cyclin D1a nor D1b showed any prognostic value in CRC or colon cancer patients. However, high cyclin D1a predicted benefit from adjuvant therapy measured in 5-year relapse-free survival (RFS) and CRC-specific survival (CSS) compared to surgery alone in colon cancer (P0.012 and P0.038, respectively) and especially in colon cancer stage III patients (P0.005 and P0.019, respectively) in univariate analyses. An interaction between treatment group and cyclin D1a could be shown for RFS (P0.004) and CSS (P0.025) in multivariate analysis.Conclusion:Our study identifies high cyclin D1a protein expression as a positive predictive factor for the benefit of adjuvant 5-FU/LEV treatment in colon cancer, particularly in stage III colon cancer.

AB - Background:The aim of this study was to investigate the value of the cyclin D1 isoforms D1a and D1b as prognostic factors and their relevance as predictors of response to adjuvant chemotherapy with 5-fluorouracil and levamisole (5-FU/LEV) in colorectal cancer (CRC).Methods:Protein expression of nuclear cyclin D1a and D1b was assessed by immunohistochemistry in 335 CRC patients treated with surgery alone or with adjuvant therapy using 5-FU/LEV. The prognostic and predictive value of these two molecular markers and clinicopathological factors were evaluated statistically in univariate and multivariate survival analyses.Results:Neither cyclin D1a nor D1b showed any prognostic value in CRC or colon cancer patients. However, high cyclin D1a predicted benefit from adjuvant therapy measured in 5-year relapse-free survival (RFS) and CRC-specific survival (CSS) compared to surgery alone in colon cancer (P0.012 and P0.038, respectively) and especially in colon cancer stage III patients (P0.005 and P0.019, respectively) in univariate analyses. An interaction between treatment group and cyclin D1a could be shown for RFS (P0.004) and CSS (P0.025) in multivariate analysis.Conclusion:Our study identifies high cyclin D1a protein expression as a positive predictive factor for the benefit of adjuvant 5-FU/LEV treatment in colon cancer, particularly in stage III colon cancer.

KW - Colorectal cancer

KW - Cyclin D1a

KW - Cyclin D1b

KW - IHC

KW - Treatment response

UR - http://www.scopus.com/inward/record.url?scp=84869089879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869089879&partnerID=8YFLogxK

U2 - 10.1038/bjc.2012.463

DO - 10.1038/bjc.2012.463

M3 - Article

C2 - 23099809

AN - SCOPUS:84869089879

SN - 0007-0920

VL - 107

SP - 1684

EP - 1691

JO - British journal of cancer

JF - British journal of cancer

IS - 10

ER -

Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this